BridgeBio Pharma, Inc. financial data

Symbol
BBIO on Nasdaq
Industry
Pharmaceutical Preparations
Location
3160 Porter Dr., Suite 250, Palo Alto, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
BridgeBio Pharma LLC (to 5/16/2019)
Latest financial report
10-Q - Q2 2024 - Aug 1, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 469 % -3.65%
Debt-to-equity -159 % -7.03%
Operating Margin -233 % +97.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 188M shares +15.7%
Common Stock, Shares, Outstanding 188M shares +16.5%
Entity Public Float 2.08B USD +112%
Common Stock, Value, Issued 194K USD +15.5%
Weighted Average Number of Shares Outstanding, Basic 188M shares +16.9%
Weighted Average Number of Shares Outstanding, Diluted 188M shares +16.9%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 219M USD +3761%
Cost of Revenue 2.39M USD -0.17%
Research and Development Expense 511M USD +33.2%
Costs and Expenses 729M USD +36%
Operating Income (Loss) -510M USD +3.83%
Nonoperating Income (Expense) 48.8M USD
Income Tax Expense (Benefit) 0 USD
Earnings Per Share, Basic -2.64 USD/shares +29.4%
Earnings Per Share, Diluted -2.64 USD/shares +29.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 408M USD +34.9%
Marketable Securities, Current 39.8M USD +29%
Assets, Current 616M USD +42.4%
Property, Plant and Equipment, Net 9.84M USD -24.6%
Operating Lease, Right-of-Use Asset 7.27M USD -26%
Intangible Assets, Net (Excluding Goodwill) 25.1M USD -8.69%
Other Assets, Noncurrent 18.9M USD -7.34%
Assets 794M USD +57.7%
Accounts Payable, Current 18.1M USD +368%
Employee-related Liabilities, Current 29.1M USD +1.28%
Liabilities, Current 134M USD +22%
Operating Lease, Liability, Noncurrent 7.06M USD -35.3%
Other Liabilities, Noncurrent 485K USD -96.4%
Liabilities 1.88B USD +1.25%
Accumulated Other Comprehensive Income (Loss), Net of Tax -4K USD -106%
Retained Earnings (Accumulated Deficit) -2.67B USD -20.5%
Stockholders' Equity Attributable to Parent -1.09B USD +19.8%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -1.08B USD +19.9%
Liabilities and Equity 794M USD +57.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -220M USD -52.1%
Net Cash Provided by (Used in) Financing Activities 280M USD +86.1%
Net Cash Provided by (Used in) Investing Activities 22.8M USD +85%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 194M shares +15.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 82.8M USD +354%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 550M USD +69.3%
Interest Paid, Excluding Capitalized Interest, Operating Activities 35.3M USD +60.1%
Deferred Tax Assets, Valuation Allowance 672M USD +25.9%
Deferred Tax Assets, Gross 679M USD +25.9%
Operating Lease, Liability 11.7M USD -20.5%
Payments to Acquire Property, Plant, and Equipment 695K USD +5692%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -454M USD +20.7%
Lessee, Operating Lease, Liability, to be Paid 13M USD -23%
Operating Lease, Liability, Current 4.62M USD +22.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.28M USD -42.4%
Lessee, Operating Lease, Liability, to be Paid, Year One 5.1M USD +9.55%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.3M USD -39.9%
Lessee, Operating Lease, Liability, to be Paid, Year Three 459K USD -75.6%
Deferred Tax Assets, Operating Loss Carryforwards 359M USD +10.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 25M shares 0%
Unrecognized Tax Benefits 30.9M USD +14.2%
Lessee, Operating Lease, Liability, to be Paid, Year Four 459K USD -46.7%
Operating Lease, Payments 1.6M USD +27.6%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 2.4M USD +14.3%
Depreciation, Depletion and Amortization 1.6M USD -2.27%
Deferred Tax Assets, Net of Valuation Allowance 6.47M USD +25.5%
Share-based Payment Arrangement, Expense 115M USD +24.8%
Interest Expense 87M USD +8.01%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%